Capricor Therapeutics (CAPR) FCF Margin (2016 - 2024)
Historic FCF Margin for Capricor Therapeutics (CAPR) over the last 16 years, with Q4 2024 value amounting to 52.96%.
- Capricor Therapeutics' FCF Margin rose 475700.0% to 52.96% in Q4 2024 from the same period last year, while for Sep 2025 it was 217.5%, marking a year-over-year decrease of 832100.0%. This contributed to the annual value of 102.91% for FY2024, which is 39700.0% up from last year.
- Capricor Therapeutics' FCF Margin amounted to 52.96% in Q4 2024, which was up 475700.0% from 515.18% recorded in Q3 2024.
- Over the past 5 years, Capricor Therapeutics' FCF Margin peaked at 129.32% during Q1 2023, and registered a low of 18558.95% during Q3 2020.
- For the 5-year period, Capricor Therapeutics' FCF Margin averaged around 2729.87%, with its median value being 453.73% (2024).
- In the last 5 years, Capricor Therapeutics' FCF Margin tumbled by -173965900bps in 2020 and then skyrocketed by 18897900bps in 2021.
- Capricor Therapeutics' FCF Margin (Quarter) stood at 7142.52% in 2020, then skyrocketed by 67bps to 2370.08% in 2021, then surged by 67bps to 791.34% in 2022, then skyrocketed by 87bps to 100.53% in 2023, then skyrocketed by 47bps to 52.96% in 2024.
- Its FCF Margin stands at 52.96% for Q4 2024, versus 515.18% for Q3 2024 and 310.94% for Q2 2024.